Reactive Arthritis after BCG Therapy in Bladder Carcinoma

Bladder cancer is a common malignancy in women and is the fourth most common malignancy in men. Bladder cancer ranges from nonaggressive and usually noninvasive tumors that recur and require long-term invasive follow-up to aggressive and invasive tumors with high disease-specific mortality. Bacillus Calmette Guerin (BCG) intravesical immunotherapy, a vaccine derived from attenuated Mycobacterium strains - Bovis is one of the most effective bladder cancer therapies currently available. Reactive arthritis has occurred in between 0.5% and 1% of bladder cancer patients treated with intravesical BCG immunotherapy. Here, we present a 66-year-old man diagnosed with urothelial carcinoma undergoing intravesical BCG therapy with high-grade fever and polyarthralgia.